When was Neurxstem founded?

Neurxstem was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Neurxstem located?

Neurxstem is headquartered in Columbus, United States.

Who is the current CEO of Neurxstem?

Rene Anand of Neurxstem. They have also founded 1 company.

How many employees does Neurxstem have?

As of Aug 31, 2026, the latest employee count at Neurxstem is 7.

Is Neurxstem a funded company?

Neurxstem is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on May 01, 2020.

When was the latest funding round of Neurxstem?

Neurxstem's latest funding was a $***** Grant (prize money) round on May 01, 2020, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does Neurxstem rank among its competitors?

Neurxstem ranks 1659th amongst 2896 active competitors, of which 975 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Neurxstem?

Neurxstem's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Neurxstem - 2026 Company Profile, Team, Funding & Competitors

Neurxstem is a funded company based in Columbus (United States), founded in 2016 by Rene Anand. It operates as a Developer of a neural organoid platform. Neurxstem has raised an undisclosed amount in funding. The company has 2896 active competitors, including 975 funded and 714 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of a neural organoid platform. The company has proprietary technology to grow synthetic neural organoids from iPSC derived from skin cells. The neuronal organoid has an application to study human brain disease mechanisms, developed diagnostic tests, and facilitate drug discovery, efficacy, and safety testing.

Website: neurxstem.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Columbus, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), May 01, 2020, $*****

Investors

HHS

Ranked

1659^th among 2896 active competitors

Employee Count

7 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 598 more

View Neurxstem's full profile

Neurxstem has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on May 01, 2020 for $*****. 1 investor participated in its latest round. Neurxstem has 1 institutional investor.

Here is the list of recent funding rounds of Neurxstem:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 01, 2020	8281232	Grant (prize money)	1538486	2964040	4400110	8592834

Access funding benchmarks and valuations. Sign up today!

View details of Neurxstem's funding rounds and investors

The founders of Neurxstem is Rene Anand. Rene Anand is the CEO of Neurxstem.

Here are the details of Neurxstem's key team members:

Rene Anand: Founder & CEO of Neurxstem.
Contact Info: 1 email address

View details of Neurxstem's Founder profiles and Board Members

Neurxstem's employee count trend

Neurxstem has 7 employees as of Aug 26. Here is Neurxstem's employee count trend over the years:

Uncover Neurxstem's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurxstem include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Neurxstem, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
1659th	Neurxstem 2016, Columbus (United States), Funding Raised	Developer of a neural organoid platform	-	HHS	29/100